drugset / Trial / NCT04497584
Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC
NaSingle-groupOpen-labelTreatment
Summary
To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC
Timeline
- Start
- 2021-08-04
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Subject | Prednisone | Other / unclassified | 40 mg | Oral |